Skip to content

Psychotherapy and combination treatment

TL;DR — Structured psychotherapies are effective acute treatments for adult depression; differences among bona fide therapies are usually smaller than differences in access, fidelity, and fit. A network meta-analysis found psychotherapy and pharmacotherapy broadly comparable head-to-head, while combination treatment improved response over either alone (RR approximately 1.25–1.27) and was more acceptable than medication alone (Cuijpers 2020, PMID 31922679). CBT, behavioral activation, interpersonal psychotherapy, problem-solving therapy, and other structured approaches have evidence, but trial effects are vulnerable to publication bias and cannot be blinded like pills. Sequential psychotherapy after medication response can reduce relapse risk (Guidi 2021, PMID 33237285). Patient preference matters because attendance and alliance are part of treatment dose.

Modalities

Therapy Core target Typical structure Evidence signal
CBT behavior, appraisals, avoidance, skills structured, homework-based large evidence base
Behavioral activation avoidance and reduced reinforcement activity monitoring and graded action effective; simpler mechanism
IPT role transitions, grief, disputes, deficits time-limited interpersonal focus established acute option
Problem-solving practical stressors and coping structured problem definition/action useful in primary care
Mindfulness-based cognitive therapy relapse-related reactivity group skills, often after remission strongest for recurrence prevention
Psychodynamic therapy relational and affective patterns variable duration evidence exists; more heterogeneous

Across major psychotherapies, network meta-analysis supports efficacy and acceptability, with limited confidence in fine-grained rankings (Cuijpers 2021, PMID 34002502). Behavioral activation performs comparably to more elaborate CBT components in network analysis (Ciharova 2021, PMID 34264703) and is supported by Cochrane review (Uphoff 2020, PMID 32628293).

Psychotherapy versus medication

Direct comparisons generally find similar acute average efficacy, though populations, therapist expertise, and medication management differ. In moderate-to-severe depression, cognitive therapy performed similarly to medication acutely in a landmark trial when delivered by experienced clinicians (DeRubeis 2005, PMID 15809408).

Dimension Psychotherapy Medication
Onset weeks; skill acquisition weeks for conventional agents
Adverse effects distress, time/cost, possible deterioration physiological and interaction burden
Availability therapist bottleneck prescriber/pharmacy access
Blinding impossible imperfect but feasible
Post-treatment durability skills may persist benefit often depends on continuation
Preference high for some patients high for others; shared decision needed

Combination treatment

In 101 randomized trials, combined psychotherapy and pharmacotherapy outperformed pharmacotherapy alone (response RR 1.27) and psychotherapy alone (RR 1.25); combination was more acceptable than medication alone (Cuijpers 2020, PMID 31922679). Relative effects do not mean every patient requires both at outset: absolute benefit, severity, chronicity, preference, and access should determine sequencing.

Sequential combination—adding psychotherapy after acute pharmacologic response—reduced relapse/recurrence in systematic review and may limit indefinite medication exposure for some patients (Guidi 2021, PMID 33237285).

Rapid-acting treatment creates a distinct sequencing question. Among 28 ketamine responders randomized to CBT or treatment as usual, the prespecified MADRS trajectory did not differ significantly, although QIDS favored CBT (Wilkinson 2021, PMID 34186531). In a 93-person esketamine trial enrolling people with major depression and suicidal ideation, CBT improved several—but not all—suicidality and depression measures through week 18 (Wilkinson 2026, PMID 42095692). These early trials support feasibility, not a settled claim that psychotherapy reliably extends every ketamine-class response.

Fidelity and common factors

Therapy labels hide variation in competence, alliance, session number, homework engagement, cultural fit, and supervision. Nonspecific factors such as hope, attention, structure, and a credible rationale contribute, but do not make modality-specific techniques irrelevant.

Trial bias Direction of concern
No participant/therapist blinding expectancy favors preferred treatment
Wait-list controls can inflate effects relative to active controls
Research therapists may overestimate routine-care effectiveness
Selective outcome reporting favors positive symptom scales
Therapist clustering ignored confidence intervals too narrow
Short follow-up durability unknown

Digital and scalable formats

Guided internet CBT can extend reach, but adherence and digital exclusion matter. Individual-participant component analysis supports decomposing and personalizing internet CBT, while also showing that human support and engagement are treatment ingredients (Furukawa 2021, PMID 33957075). Digital delivery is not automatically low-resource if crisis response, coaching, and privacy safeguards are adequate.

Exercise and lifestyle as structured treatment

Exercise is not psychotherapy, but it frequently sits in the same nonpharmacologic pathway. A 2024 network meta-analysis found clinically meaningful effects across walking/jogging, yoga, strength training, and mixed aerobic exercise, with intensity and supervision affecting outcomes (Noetel 2024, PMID 38355154). WFSBP/ASLM guidelines formalize lifestyle-based care while emphasizing adjunctive, individualized use (Marx 2023, PMID 36202135).

Measurement and deterioration

Routine symptom and function measurement detects stagnation and worsening. Measurement-based care improved outcomes in a randomized study (Guo 2015, PMID 26315978). Psychotherapy trials and services should report reliable deterioration, adverse events, dropout reasons, and functional outcomes—not only mean symptom improvement.

Psychotherapy evidence deepening

Psychotherapy is not one exposure: modality, therapist competence, session number, delivery medium, comparator intensity, and patient preference all change the estimand.

Comparison Evidence direction Important qualifier
Psychotherapy vs medication Average acute effects are similar in network evidence Trials differ in blinding possibilities, allegiance, and missingness
Combination vs either alone Combination improves response on average Added visits, cost, and adverse effects alter net benefit
CBT vs behavioral activation Both have evidence; component networks often show small between-modality differences Therapist and setting effects can exceed named-school differences
Guided vs unguided internet therapy Guidance generally improves engagement and effect Digital exclusion and adherence reduce population effectiveness
Exercise vs inactive control Meta-analyses show symptom benefit Expectancy, attention controls, dose, and baseline activity vary
Relapse-prevention psychotherapy Continuation cognitive approaches can reduce recurrence Evidence is strongest in selected remitted/recurrent populations

Future trials should report deterioration, functioning, treatment burden, therapist clustering, and longer-term recurrence—not symptom means alone.

Additional live-search evidence ledger

The records below were added after full PubMed E-utilities retrieval on 2026-08-30. The ledger states the evidentiary role of each record and preserves the design limitation that should travel with its citation.

  • Cipriani A 2018 — Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Cipriani A 2018, PMID 29477251)

  • Simon GE 2024 — Management of Depression in Adults: A Review. Review-level synthesis; conclusions inherit limitations of the underlying designs. (Simon GE 2024, PMID 38856993)

  • Zaccoletti D 2026 — Comparison of antidepressant deprescribing strategies in individuals with clinically remitted depression: a systematic review and network meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Zaccoletti D 2026, PMID 41386898)

  • Ng MY 2023 — How do cognitive behavioral therapy and interpersonal psychotherapy improve youth depression? Applying meta-analytic structural equation modeling to three decades of randomized trials. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Ng MY 2023, PMID 38713748)

  • Fukumori M 2024 — Network meta-analysis of the effectiveness of psychotherapies with or without medication for treating adult depression. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Fukumori M 2024, PMID 39565153)

  • Wilson KC 2008 — Psychotherapeutic treatments for older depressed people. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Wilson KC 2008, PMID 18254062)

  • Zhou Y 2023 — Psychological interventions for the prevention of depression relapse: systematic review and network meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Zhou Y 2023, PMID 37770471)

  • Sankar A 2018 — A systematic review and meta-analysis of the neural correlates of psychological therapies in major depression. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Sankar A 2018, PMID 30081291)

  • Cuijpers P 2020 — The effects of fifteen evidence-supported therapies for adult depression: A meta-analytic review. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Cuijpers P 2020, PMID 31394976)

  • Couch E 2025 — Effectiveness of Psychological Therapies for Depression During the Perinatal Period : A Systematic Review and Meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Couch E 2025, PMID 41183344)

  • Nowrouzi-Kia B 2025 — Evaluating the Efficacy of Telehealth-Based Treatments for Depression in Adults: A Rapid Review and Meta-Analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Nowrouzi-Kia B 2025, PMID 39485666)

  • Köhler-Forsberg O 2023 — Efficacy and Safety of Antidepressants in Patients With Comorbid Depression and Medical Diseases: An Umbrella Systematic Review and Meta-Analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Köhler-Forsberg O 2023, PMID 37672261)

  • Chen H 2022 — Effectiveness of CBT and its modifications for prevention of relapse/recurrence in depression: A systematic review and meta-analysis of randomized controlled trials. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Chen H 2022, PMID 36162683)

  • Kuyken W 2016 — Efficacy of Mindfulness-Based Cognitive Therapy in Prevention of Depressive Relapse: An Individual Patient Data Meta-analysis From Randomized Trials. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Kuyken W 2016, PMID 27119968)

  • Santoft F 2019 — Cognitive behaviour therapy for depression in primary care: systematic review and meta-analysis. Meta-analysis; heterogeneity, comparator choice, and reporting bias govern interpretation. (Santoft F 2019, PMID 30688184)

Open questions

  • Which components add benefit beyond a credible structured therapeutic relationship (Ciharova 2021, PMID 34264703)?
  • Who benefits enough from initial combination to justify added burden (Cuijpers 2020, PMID 31922679)?
  • Can scalable digital therapy preserve engagement, safety, and equity (Furukawa 2021, PMID 33957075)?
  • What maintenance sequence best prevents recurrence with the lowest long-term treatment burden (Guidi 2021, PMID 33237285)?

References

  1. Cuijpers P, et al. Psychotherapies, pharmacotherapies and their combination in adult depression. World Psychiatry. 2020. PMID 31922679
  2. Cuijpers P, et al. Psychotherapies for depression: network meta-analysis. World Psychiatry. 2021. PMID 34002502
  3. Ciharova M, et al. Cognitive restructuring, behavioral activation and CBT in adult depression. Journal of Consulting and Clinical Psychology. 2021. PMID 34264703
  4. Uphoff E, et al. Behavioural activation therapy for depression in adults. Cochrane Database of Systematic Reviews. 2020. PMID 32628293
  5. DeRubeis RJ, et al. Cognitive therapy vs medications in moderate to severe depression. Archives of General Psychiatry. 2005. PMID 15809408
  6. Guidi J, et al. Sequential combination of pharmacotherapy and psychotherapy in MDD. JAMA Psychiatry. 2021. PMID 33237285
  7. Furukawa TA, et al. Personalising internet CBT for depression. Lancet Psychiatry. 2021. PMID 33957075
  8. Noetel M, et al. Effect of exercise for depression: network meta-analysis. BMJ. 2024. PMID 38355154
  9. Marx W, et al. Lifestyle-based mental health care guidelines for MDD. World Journal of Biological Psychiatry. 2023. PMID 36202135
  10. Guo T, et al. Measurement-Based Care Versus Standard Care for Major Depression. American Journal of Psychiatry. 2015. PMID 26315978
  11. Cipriani A, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet (London, England). 2018;391:1357-1366. PMID 29477251
  12. Simon GE, et al. Management of Depression in Adults: A Review. JAMA. 2024;332:141-152. PMID 38856993
  13. Zaccoletti D, et al. Comparison of antidepressant deprescribing strategies in individuals with clinically remitted depression: a systematic review and network meta-analysis. The lancet. Psychiatry. 2026;13:24-36. PMID 41386898
  14. Ng MY, et al. How do cognitive behavioral therapy and interpersonal psychotherapy improve youth depression? Applying meta-analytic structural equation modeling to three decades of randomized trials. Psychological bulletin. 2023;149:507-548. PMID 38713748
  15. Fukumori M, et al. Network meta-analysis of the effectiveness of psychotherapies with or without medication for treating adult depression. Acta neuropsychiatrica. 2024;36:423-437. PMID 39565153
  16. Wilson KC, et al. Psychotherapeutic treatments for older depressed people. The Cochrane database of systematic reviews. 2008:CD004853. PMID 18254062
  17. Zhou Y, et al. Psychological interventions for the prevention of depression relapse: systematic review and network meta-analysis. Translational psychiatry. 2023;13:300. PMID 37770471
  18. Sankar A, et al. A systematic review and meta-analysis of the neural correlates of psychological therapies in major depression. Psychiatry research. Neuroimaging. 2018;279:31-39. PMID 30081291
  19. Cuijpers P, et al. The effects of fifteen evidence-supported therapies for adult depression: A meta-analytic review. Psychotherapy research : journal of the Society for Psychotherapy Research. 2020;30:279-293. PMID 31394976
  20. Couch E, et al. Effectiveness of Psychological Therapies for Depression During the Perinatal Period : A Systematic Review and Meta-analysis. Annals of internal medicine. 2025;178:1752-1762. PMID 41183344
  21. Nowrouzi-Kia B, et al. Evaluating the Efficacy of Telehealth-Based Treatments for Depression in Adults: A Rapid Review and Meta-Analysis. Journal of occupational rehabilitation. 2025;35:703-724. PMID 39485666
  22. Köhler-Forsberg O, et al. Efficacy and Safety of Antidepressants in Patients With Comorbid Depression and Medical Diseases: An Umbrella Systematic Review and Meta-Analysis. JAMA psychiatry. 2023;80:1196-1207. PMID 37672261
  23. Chen H, et al. Effectiveness of CBT and its modifications for prevention of relapse/recurrence in depression: A systematic review and meta-analysis of randomized controlled trials. Journal of affective disorders. 2022;319:469-481. PMID 36162683
  24. Kuyken W, et al. Efficacy of Mindfulness-Based Cognitive Therapy in Prevention of Depressive Relapse: An Individual Patient Data Meta-analysis From Randomized Trials. JAMA psychiatry. 2016;73:565-74. PMID 27119968
  25. Santoft F, et al. Cognitive behaviour therapy for depression in primary care: systematic review and meta-analysis. Psychological medicine. 2019;49:1266-1274. PMID 30688184
  26. Wilkinson ST, et al. Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial. Psychotherapy and Psychosomatics. 2021;90:318-327. PMID 34186531
  27. Wilkinson ST, et al. Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial. Journal of Clinical Psychiatry. 2026;87:25m16285. PMID 42095692